Curis Inc (CRIS) Stock Price & Analysis
Curis Inc (CRIS) rose 4.71% to USD 4.89 as of July 25, 2026 at 06:53 UTC, according to Nexqual real-time market data.
CRIS last closed at USD 4.67; the session ranged USD 4.8–5.25 on volume of 108,414 shares. Market capitalization is $9.53M, with a 52-week range of USD 3.6–39 (NCM). Source: Nexqual, July 25, 2026 at 06:53 UTC.
Key Statistics (as of July 25, 2026 at 06:53 UTC)
| Price | USD 4.89 |
|---|---|
| Change | ▲ 4.71% (up) |
| Previous Close | USD 4.67 |
| Open | USD 4.98 |
| Day Range | USD 4.8 – 5.25 |
| 52-Week Range | USD 3.6 – 39 |
| Volume | 108,414 shares |
| Market Cap | $9.53M |
| Exchange | NCM |
Technical Analysis (CRIS)
Nexqual's technical model rates CRIS "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:53 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.33 (neutral) |
| vs SMA50 | Below (USD 7.78) |
| MACD | -0.96 (negative) |
Analyst Ratings (CRIS)
Wall Street analysts rate CRIS "Strong Buy" based on 3 analysts, with a mean price target of USD 69.33 (range USD 43–100), per Nexqual as of July 25, 2026 at 06:53 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 69.33 |
| High Target | USD 100 |
| Low Target | USD 43 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (CRIS)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -5.21 |
| Revenue Estimate | $750,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -25 vs est -5.8 ▼ miss |
| 2025-12-31 | USD -9.95 vs est -8.65 ▼ miss |
| 2025-09-30 | USD -9.8 vs est -12 ▲ beat |
| 2025-06-30 | USD -13.6 vs est -30.3 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:53 UTC.
Financials & Fundamentals (CRIS)
| Total Revenue | $7.06M |
|---|---|
| Gross Margin | -272.49% |
| Operating Margin | -485.12% |
| Profit Margin | -299.66% |
| ROE | -693.93% |
| Debt / Equity | 10.52 |
| Current Ratio | 1.11 |
| Total Cash | $15.00M |
| Total Debt | $1.34M |
| Free Cash Flow | $-13.81M |
Source: Nexqual, July 25, 2026 at 06:53 UTC.
Financial Health Score (CRIS)
Nexqual rates Curis Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:53 UTC.
| Growth | Critical — Revenue -13% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $15M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$14M, burning cash |
| Efficiency | Critical — ROE -694%, ROA -62.1% |
Ownership (CRIS)
| Insider Ownership | +8.03% |
|---|---|
| Institutional Ownership | +40.50% |
| Shares Outstanding | 1.95M |
| Float | 1.38M |
| Short % of Float | +5.47% |
Source: Nexqual, July 25, 2026 at 06:53 UTC.
Leadership (CRIS)
Curis Inc is led by James E. Dentzer (age 58), President, CEO, Secretary, Treasurer & Director, per Nexqual as of July 25, 2026 at 06:53 UTC.
| President, CEO, Secretary, Treasurer & Director | James E. Dentzer (age 58) |
|---|---|
| CFO and Principal Financial & Accounting Officer | Diantha Duvall (age 53) |
| Vice President of Technology Management & Intellectual Property | Mark W. Noel (age 66) |
| Senior Director of Human Resources | Rachel Blasbalg |
Major Backers & Investors (CRIS)
Notable institutional backers of Curis Inc include Bleichroeder LP, Stonepine Capital Management, LLC, Nantahala Capital Management, LLC, according to Nexqual as of July 25, 2026 at 06:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bleichroeder LP | 0.49% |
| Stonepine Capital Management, LLC | 0.48% |
| Nantahala Capital Management, LLC | 0.26% |
| Sphera Funds Management Ltd. | 0.26% |
| Cable Car Capital, LP | 0.17% |
Source: Nexqual, July 25, 2026 at 06:53 UTC.
From Curis Inc's Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- In March 2025, we announced that we had completed productive meetings with both the European Committee for Medicinal Products for Human Use, or CHMP, and the FDA on the suitability of using the ongoing TakeAim Lymphoma Phase 1/2 study to support a potential accelerated regulatory path for a Conditional Marketing Authorization, or CMA, submission in Europe and a New Drug Application, or NDA, submission in the U.S.
- With passage of the FDA's Modernization Act 2.0 in December 2022, Congress eliminated provisions in both the FDCA and the Public Health Service Act, or PHSA, that required animal testing in support of an NDA.
- FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the drug under a treatment protocol, or Treatment IND Application.
- Intellectual Property Our policy is to obtain and enforce the patents and proprietary technology rights that are key to our business.
Partnerships
- In conjunction with the October 2016 exercise of our option to license the PD-L1/TIM3 program under our collaboration with Aurigene and the March 2018 exercise of our option to the fourth program in immuno-oncology, we obtained world-wide (except for India and Russia) exclusive licenses to the Aurigene intellectual 11 Table o f Contents property relevant to the program.
- We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AGEN | Agenus Inc. | USD 5.98 | ▲ 8.14% |
| RIGL | Rigel Pharmaceuticals, Inc. | USD 36.74 | ▼ 2.8% |
| LXRX | Lexicon Pharmaceuticals, Inc. | USD 2.29 | ▲ 1.78% |
| CLDX | Celldex Therapeutics, Inc. | USD 35.28 | ▲ 1.47% |
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 9.34 | ▼ 1.79% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:53 UTC. This page is informational and not investment advice.